Related Experiment Video

Updated: Jul 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Recent patents on nucleoside and nucleotide inhibitors for HCV

Jae H Shim1, Zhi Hong, Jim Z Wu

  • 1Drug Discovery, Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, California 92626, USA. jshim@valeant.com

Recent Patents on Anti-Infective Drug Discovery
|January 29, 2008
PubMed

Insights

New patents show promising nucleoside and nucleotide inhibitors for Hepatitis C virus (HCV) infection. These drugs target viral polymerases, offering potential new treatments for the 170 million people chronically infected worldwide.

Area of Science:

  • Hepatology
  • Virology
  • Medicinal Chemistry

Background:

  • Hepatitis C virus (HCV) infection is a major global health concern, leading to liver cirrhosis and cancer.
  • An estimated 170 million individuals worldwide suffer from chronic HCV infection.
  • Current therapeutic options for HCV are limited, driving the need for novel drug development.

Purpose of the Study:

  • To review recent patents on nucleoside and nucleotide inhibitors for HCV treatment.
  • To analyze the chemical structures, biological activities, and mechanisms of action of these inhibitors.
  • To discuss drug resistance profiles and the development status of promising candidates.

Main Methods:

  • Comprehensive review of patent literature concerning nucleoside and nucleotide inhibitors for HCV.
  • Analysis of claimed chemical entities and their associated biological data.
  • Evaluation of reported mechanisms of action and drug resistance patterns.

Main Results:

  • Numerous patents have been filed for novel nucleoside and nucleotide inhibitors targeting HCV.
  • These compounds function as chain terminators, mutagens, or competitive inhibitors of viral polymerases.
  • Several promising nucleoside inhibitors are in various stages of development, with detailed activity and resistance data.

Conclusions:

  • Nucleoside and nucleotide inhibitors represent a significant area of research and development for anti-HCV therapeutics.
  • Patent activity highlights ongoing innovation in designing effective and safe treatments for HCV.
  • Further development of these inhibitors holds promise for improving outcomes for chronically infected patients.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...